Telix Pharmaceuticals Ltd has released a press release.
ProstACT Phase III Study Clinical Development Update
Filed with ASX ·
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call6ix hasn’t read this filing yet.
Telix Pharmaceuticals Limited on 6ix
In the deck
Earlier from Telix Pharmaceuticals
- Telix and DuChemBio - South Korea Partnership
- Briefing for Investor call - TheraPharm GmbH Acquisition
- Acquisition of TheraPharm GmbH - Investor Call
- Telix Acquires TheraPharm GmbH
- Prostate Cancer Therapy FDA Meeting Update
Later from Telix Pharmaceuticals
- TGA Priority Review Granted for Prostate Cancer Imaging
- FDA New Drug Application for TLX591-CDx Proceeds to Review
- Telix Completes Acquisition of TheraPharm GmbH
- IP Agreement with U Southampton for access to TRALA data
- New Drug Submission filed with Health Canada for TLX591-CDx
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals